SEC Filing Summary for Aclaris Therapeutics, Inc.

Christopher P. Molineaux, a director at Aclaris Therapeutics, Inc. (ACRS), reported several transactions on June 4th and 5th, 2026. On June 4th, Molineaux acquired 42,350 Stock Options (right to buy) with a conversion price of $4.71 and 10,987 Restricted Stock Units (RSUs). These RSUs vest on June 4, 2027. On June 5th, Molineaux acquired 11,580 shares of Common Stock and disposed of 11,580 Restricted Stock Units that vested on June 5, 2026. Following these transactions, Molineaux holds 42,350 shares via options, 10,987 RSUs, and 69,536 shares of Common Stock directly.